{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:51:36Z","timestamp":1765893096824,"version":"3.48.0"},"reference-count":42,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>The advances that have marked the history of hemophilia represent a concrete example of therapeutic evolution.The progress made over the years has been able to revolutionize its treatment, bringing about a radical changeboth in the therapeutic algorithm and in life expectancy. Considering the recent milestones achieved, it would beanachronistic to maintain the same therapeutic goals as in the past; the normalization of hemostasis is the pathleading to the ultimate therapeutic goal, which should be the achievement of health equity: a life comparable tothat of a person without such a condition.This article highlights the need for a multidisciplinary approach to the management of hemophilia, as raisedfrom the different perspectives of the stakeholders who contributed: pharmacologists, patients, clinicians,bioethicists, pain therapists, and pharmacoeconomists. This has made it possible to gain a comprehensive viewthat reflects the complexity of managing a chronic disease such as hemophilia.<\/jats:p>","DOI":"10.33393\/grhta.2025.3618","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:47:02Z","timestamp":1765892822000},"page":"256-264","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic evolution: translating pharmacological innovation in tangible benefit for people with hemophilia A. A multistakeholder perspective"],"prefix":"10.33393","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-3819","authenticated-orcid":false,"given":"Matteo Nicola Dario","family":"Di Minno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3916-1293","authenticated-orcid":false,"given":"Valentina","family":"Drago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-3798","authenticated-orcid":false,"given":"Andrea","family":"Marcellusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5403-7909","authenticated-orcid":false,"given":"Salvatore","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consalvo","family":"Mattia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0567-0260","authenticated-orcid":false,"given":"Enrico","family":"Ferri Grazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-5223","authenticated-orcid":false,"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Fornasari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18642","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"18154","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(S6)(suppl 6):1-158. https:\/\/doi.org\/10.1111\/hae.14046 PMID:32744769","DOI":"10.1111\/hae.14046"},{"key":"18155","unstructured":"Cortes GA, Moore MJ, El-Nakeep S. Physiology, Von Willebrand Factor. 2023 Feb 20. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 PMID: 32644488"},{"key":"18156","doi-asserted-by":"crossref","unstructured":"Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: current knowledge and future perspectives. J Thromb Haemost. 2021;19(9):2112-2121. https:\/\/doi.org\/10.1111\/jth.15444 PMID:34197690","DOI":"10.1111\/jth.15444"},{"key":"18157","doi-asserted-by":"crossref","unstructured":"Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia. 2020;26(1):17-24. https:\/\/doi.org\/10.1111\/hae.13862 PMID:31724316","DOI":"10.1111\/hae.13862"},{"key":"18158","doi-asserted-by":"crossref","unstructured":"Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med. 2013;4:49-56. https:\/\/doi.org\/10.2147\/JBM.S43734 PMID:23700376","DOI":"10.2147\/JBM.S43734"},{"key":"18159","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545-553. https:\/\/doi.org\/10.3324\/haematol.2019.232132 PMID:32060150","DOI":"10.3324\/haematol.2019.232132"},{"key":"18160","doi-asserted-by":"crossref","unstructured":"Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: the ups and downs of treatment. Blood Rev. 2021;50:100852. https:\/\/doi.org\/10.1016\/j.blre.2021.100852 PMID:34243987","DOI":"10.1016\/j.blre.2021.100852"},{"key":"18161","doi-asserted-by":"crossref","unstructured":"Blair HA. Valoctocogene Roxaparvovec: first Approval. Drugs. 2022;82(14):1505-1510. https:\/\/doi.org\/10.1007\/s40265-022-01788-y PMID:36214970","DOI":"10.1007\/s40265-022-01788-y"},{"key":"18162","doi-asserted-by":"crossref","unstructured":"Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv. 2020;4(9):2111-2118. https:\/\/doi.org\/10.1182\/bloodadvances.2019000849 PMID:32396619","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"18163","unstructured":"Lusher JM. In: Kaushansky K, Berliner N, eds. 50 Years in Hematology: Research That Revolutionized Patient Care. Washington, DC: American Society of Hematology; 2008:25-27. Online https:\/\/www.hematology.org\/about\/history\/50-years"},{"key":"18164","doi-asserted-by":"crossref","unstructured":"Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187-197. https:\/\/doi.org\/10.1016\/S0140-6736(15)01123-X PMID:26897598","DOI":"10.1016\/S0140-6736(15)01123-X"},{"key":"18165","doi-asserted-by":"crossref","unstructured":"White GC. Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure. Trans Am Clin Climatol Assoc. 2010;121:61-73. PMID:20697550","DOI":"10.1176\/ps.2010.61.2.121"},{"key":"18166","doi-asserted-by":"crossref","unstructured":"Raso S, Hermans C. Recombinant factor VIII: past, present and future of treatment of hemophilia A. Drugs Today (Barc). 2018;54(4):269-281. https:\/\/doi.org\/10.1358\/dot.2018.54.4.2800622 PMID:29869648","DOI":"10.1358\/dot.2018.54.4.2800622"},{"key":"18167","doi-asserted-by":"crossref","unstructured":"Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157-159. https:\/\/doi.org\/10.1038\/nbt.1601 PMID:20081867","DOI":"10.1038\/nbt.1601"},{"key":"18168","doi-asserted-by":"crossref","unstructured":"Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med. 2020;383(11):1018-1027. https:\/\/doi.org\/10.1056\/NEJMoa2002699 PMID:32905674","DOI":"10.1056\/NEJMoa2002699"},{"key":"18169","unstructured":"European Medicines Agency. Hemlibra \u2013 Summary of Product Characteristics. EMA; Last updated: 29\/04\/2024. Online https:\/\/ec.europa.eu\/health\/documents\/community-register\/2018\/20180223140159\/anx_140159_en.pdf (Accessed July 2025)"},{"key":"18170","doi-asserted-by":"crossref","unstructured":"Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295-e305. https:\/\/doi.org\/10.1016\/S2352-3026(19)30054-7 PMID:31003963","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"18171","doi-asserted-by":"crossref","unstructured":"Perrone V, Leogrande M, Cappuccilli M, Esposti LD. Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization. Blood Res. 2024;59(1):30. https:\/\/doi.org\/10.1007\/s44313-024-00034-6 PMID:39377876","DOI":"10.1007\/s44313-024-00034-6"},{"key":"18172","doi-asserted-by":"crossref","unstructured":"Madan B, Ozelo MC, Raheja P, et al. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024;22(7):1880-1893. https:\/\/doi.org\/10.1016\/j.jtha.2024.04.001 PMID:38614387","DOI":"10.1016\/j.jtha.2024.04.001"},{"key":"18173","doi-asserted-by":"crossref","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544. https:\/\/doi.org\/10.1056\/NEJMoa067659 PMID:17687129","DOI":"10.1056\/NEJMoa067659"},{"key":"18174","unstructured":"Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479-486. https:\/\/doi.org\/10.2450\/2019.0211-19 PMID:31846611"},{"key":"18175","doi-asserted-by":"crossref","unstructured":"Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677-1686. https:\/\/doi.org\/10.2147\/PPA.S139851 PMID:29033555","DOI":"10.2147\/PPA.S139851"},{"key":"18176","doi-asserted-by":"crossref","unstructured":"Valentino, Leonard A, et al. \"Personalising haemophilia management with shared decision making\" The Journal of Haemophilia Practice, vol. 8, no. 1, Haemnet Ltd, 2021:69-79. https:\/\/doi.org\/10.17225\/jhp00178","DOI":"10.17225\/jhp00178"},{"key":"18177","doi-asserted-by":"crossref","unstructured":"Malec L, Matino D. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review. Haemophilia. 2023;29(6):1419-1429. https:\/\/doi.org\/10.1111\/hae.14866 PMID:37758651","DOI":"10.1111\/hae.14866"},{"key":"18178","doi-asserted-by":"crossref","unstructured":"Roussel NA. Gaining insight into the complexity of pain in patients with haemophilia: state-of-the-art review on pain processing. Haemophilia. 2018;24(S6)(suppl 6):3-8. https:\/\/doi.org\/10.1111\/hae.13509 PMID:29878656","DOI":"10.1111\/hae.13509"},{"key":"18179","doi-asserted-by":"crossref","unstructured":"van Vulpen LFD, Holstein K, Martinoli C. Joint disease in haemophilia: Pathophysiology, pain and imaging. Haemophilia. 2018;24(S6)(suppl 6):44-49. https:\/\/doi.org\/10.1111\/hae.13449 PMID:29878659","DOI":"10.1111\/hae.13449"},{"key":"18180","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger S, Hilberg T. Neuropathic pain in patients with haemophilia, that is the question. H\u00e4mostaseologie. 2015;35(S 01)(suppl 1):S5-S9. PMID:26540131 https:\/\/doi.org\/10.1055\/s-0037-1619823 PMID:26540131","DOI":"10.1055\/s-0037-1619823"},{"key":"18181","doi-asserted-by":"crossref","unstructured":"Gopal S, Barnes RFW, Volland LM, Page D, von Drygalski A. Patient-derived assessment tool using musculoskeletal ultrasound for validation of haemarthrosis. Haemophilia. 2022;28(5):842-848. https:\/\/doi.org\/10.1111\/hae.14591 PMID:35654082","DOI":"10.1111\/hae.14591"},{"key":"18182","doi-asserted-by":"crossref","unstructured":"H\u00e4user W, Morlion B, Vowles KE, et al. European* clinical practice recommendations on opioids for chronic noncancer pain - Part 1: role of opioids in the management of chronic noncancer pain. Eur J Pain. 2021;25(5):949-968. https:\/\/doi.org\/10.1002\/ejp.1736 PMID:33655607","DOI":"10.1002\/ejp.1736"},{"key":"18183","doi-asserted-by":"crossref","unstructured":"O\u2019Brien T, Christrup LL, Drewes AM, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3-19. https:\/\/doi.org\/10.1002\/ejp.970 PMID:27991730","DOI":"10.1002\/ejp.970"},{"key":"18184","doi-asserted-by":"crossref","unstructured":"Riley RR, Witkop M, Hellman E, Akins S. Assessment and management of pain in haemophilia patients. Haemophilia. 2011;17(6):839-845. https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02567.x PMID:21645179","DOI":"10.1111\/j.1365-2516.2011.02567.x"},{"key":"18185","doi-asserted-by":"crossref","unstructured":"Di Minno MN, Ambrosino P, Franchini M, Coppola A, Di Minno G. Arthropathy in patients with moderate hemophilia a: a systematic review of the literature. Semin Thromb Hemost. 2013;39(7):723-731. https:\/\/doi.org\/10.1055\/s-0033-1354422 PMID:24022804","DOI":"10.1055\/s-0033-1354422"},{"key":"18186","unstructured":"Di Minno MND, Santoro C, Corcione A, et al; HAEMODOL Study Group (Appendix 1). Pain assessment and management in Italian Haemophilia Centres. Blood Transfus. 2021;19(4):335-342. PMID:33263519"},{"key":"18187","doi-asserted-by":"crossref","unstructured":"Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia. 2010;16(2):247-255. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02129.x PMID:19925631","DOI":"10.1111\/j.1365-2516.2009.02129.x"},{"key":"18188","doi-asserted-by":"crossref","unstructured":"Santoro C, Di Minno MND, Corcione A, et al; HAEMODOL Study Group. Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement. Blood Rev. 2022;51:100885. https:\/\/doi.org\/10.1016\/j.blre.2021.100885 PMID:34544642","DOI":"10.1016\/j.blre.2021.100885"},{"key":"18189","unstructured":"NICE. Glossary. 2016. Online https:\/\/www.nice.org.uk\/glossary?letter=q (Accessed July 2025)"},{"key":"18190","unstructured":"Ranieri I, Eid M, Marcellusi A. L\u2019impatto dei QALYs nelle malattie infiammatorie intestinali: una Revisione Sistematica della letteratura. 10 \u00b0 ISPOR Italy Rome Chapter, Roma, 4-5 dicembre 2024. Online https:\/\/www.isporitaly.org\/abstract-x-congresso-ispor\/ (Accessed July 2025)"},{"key":"18191","unstructured":"World Health Organization. Health Equity. Online https:\/\/www.who.int\/health-topics\/health-equity#tab=tab_1 (Accessed July 2025)"},{"key":"18192","unstructured":"Scholz N. Europe\u2019s Beating Cancer plan: quick overview and initial reactions. European Parliamentary Research Service; 2021."},{"key":"18193","unstructured":"Legge 30 dicembre 2024, n. 207. Bilancio di previsione dello Stato per l\u2019anno finanziario 2025 e bilancio pluriennale per il triennio 2025-2027. GU Serie Generale n.305 del 31.12.2024- Suppl. Ordinario n. 43."},{"key":"18194","unstructured":"Legge 15 marzo 2010, n. 38 \u201cDisposizioni per garantire l\u2019accesso alle cure palliative e alla terapia del dolore (GU Serie Generale n.65 del 19.03.2010)."},{"key":"18195","unstructured":"Ministero della Salute. Rapporto al Parlamento sullo stato di attuazione della legge n. 38 del 15 marzo 2010: \u201cDisposizioni per garantire l\u2019accesso alle cure palliative e alla terapia del dolore\u201d. Anni 2015- 2017. Online https:\/\/www.fedcp.org\/images\/file\/974\/rapportoparlamento.pdf (Accessed July 2025)"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3618\/4166","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3618\/4167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3618\/4167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:47:11Z","timestamp":1765892831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2025.3618","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"type":"electronic","value":"2283-5733"},{"type":"print","value":"2284-2403"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}